IBA, RaySearch Collaborate
News Sep 06, 2016
IBA and RaySearch Laboratories have entered into a long-term strategic alliance to combine their respective technologies and advance adaptive proton therapy. As part of the collaboration, the RayCare® oncology information system, which is currently in development at RaySearch, will be customized for optimal use together with the IBA delivery solutions. In both RayStation® and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components will allow for a close and seamless workflow integration with optimized performance.
The result will be a complete turnkey solution for all software and hardware needed to deliver outstanding adaptive proton therapy treatment. Proton therapy is one of the most precise forms of radiation therapy; targets can be pinpointed with the optimal radiation dose, while adjacent tissue is spared to a much higher degree than with conventional radiation therapy. The technique is growing in popularity worldwide, and studies indicate that approximately 20% of radiation therapy patients could benefit from proton therapy, while only 1% receive.
Johan Löf, Chief Executive Officer of RaySearch Laboratories, says: “IBA and RaySearch are committed to taking proton therapy to new levels. Through this collaboration with the world leader in proton therapy, we are giving clinics a complete platform that will optimize workflows and enable more precise and personalized treatment for patients. This will make it possible to realize the full potential of proton therapy.”
Olivier Legrain, Chief Executive Officer of IBA, says: “We are certain that proton therapy will improve care for an increasing percentage of cancer patients in the coming years. By combining IBA systems with RayCare and RayStation, we are creating what we see as the most comprehensive and innovative proton therapy solution available. This alliance is an important step toward adaptive proton therapy treatment that will broaden the spectrum of clinical applications and enable the best possible results for cancer patients worldwide.”
Cambridge Epigenetix, NuGEN Technologies Sign Agreement to Combine Leading Technologies in Epigenetics ResearchNews
Cambridge Epigenetix and NuGEN Technologies come together to integrate the oxidative bisulfite sequencing (oxBS-Seq) with NGS library preparation kits.READ MORE
Why Combining Two Checkpoint Inhibitors is More Effective Than Using Them in IsolationNews
A team at the MD Anderson Cancer center team has found that checkpoint inhibitors fire up different types of T cells to attack tumorsREAD MORE
Major Cause of Drug-resistance in Prostate Cancer Patients IdentifiedNews
A recent Nature Medicine paper outlines the role of mutations within the SPOP gene on the development of resistance to one class of drugs.READ MORE